Proabbly your cash runway too short IMO, given cost reductions.I...

Proabbly your cash runway too short IMO, given cost reductions.

I disagree on its pressing needs of course. This company has been so poorly managed, but its stating the obvious.....again. Obviously these guys have done awful capital management as I have said many times and are a massive risk. But its also very cheap. Financing will be easier now they have Singapore and Vietnamese approvals. And they have long been in negotiations for two partnerships (to answer your question of who and at what cost - IP and forward revenue share).

This company was always a risk, but Innoventure and the less attractive CellHeal, deals now more attractive to the suitors now. This is why this end of the market is so volatile. Its all too the moon when things are going well, and bankruptcy gloom when they don't. Usually its somewhere between. If OSX negotiates a partnership or two with upfront payments, it rides the storm and hopefully with continuing sales growth, new approval revenues, and continued better cost management it eventually goes cash flow positive, or reasonably towards it before another raise at higher levels. Maybe it doesn't. Maybe its just a pause in a journey to bankruptcy. I am happy to have a flutter.

Its gross profits are fine. Its Sales, Marketing and general admin costs were atrocious versus them however and have been reined in. Its a risky investment, but this is cheap for the potential if it continues Vietnamese growth, turns Signapore around on the approval therein and Korea's bottlenecks are indeed over....